438 results match your criteria Imaging in Drug-Induced Lung Disease


Copper-Binding Domain Variation in a Novel Murine Lysyl Oxidase Model Produces Structurally Inferior Aortic Elastic Fibers Whose Failure Is Modified by Age, Sex, and Blood Pressure.

Int J Mol Sci 2022 Jun 17;23(12). Epub 2022 Jun 17.

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Lysyl oxidase () is a copper-binding enzyme that cross-links elastin and collagen. The dominant variation contributes to familial thoracic aortic aneurysm. Previously reported murine mutants had a mild phenotype and did not dilate without drug-induced provocation. Read More

View Article and Full-Text PDF

Venlafaxine-induced interstitial lung disease with COVID-19 pandemic-related depression.

Clin Case Rep 2022 Jun 2;10(6):e05941. Epub 2022 Jun 2.

Department of Psychiatry Kaga Mental Hospital Kaga Japan.

Venlafaxine-associated pulmonary toxicity is rare, with only a few reports of pneumonitis, eosinophilic pneumonia, and asthma. We report a case of venlafaxine-induced interstitial lung disease in a patient with coronavirus disease 2019 pandemic-related depression. Chest imaging findings improved after discontinuation of venlafaxine and treatment with corticosteroids. Read More

View Article and Full-Text PDF

Myocardial Tissue Oxygenation and Microvascular Blood Volume Measurement Using a Contrast Blood Oxygenation Level-Dependent Imaging Model.

Invest Radiol 2022 Apr 13. Epub 2022 Apr 13.

From the Division of Cardiovascular Medicine, Department of Internal Medicine, Vanderbilt University Medical Center.

Objectives: We propose a method of quantitatively measuring drug-induced microvascular volume changes, as well as drug-induced changes in blood oxygenation using calibrated blood oxygen level-dependent magnetic resonance imaging (MRI). We postulate that for MRI signals there is a contribution to R2* relaxation rates from static susceptibility effects of the intravascular blood that scales with the blood volume/magnetic field and depends on the oxygenation state of the blood. These may be compared with the effects of an intravascular contrast agent. Read More

View Article and Full-Text PDF

Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment.

ESMO Open 2022 04 24;7(2):100404. Epub 2022 Feb 24.

Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; Department of Hematology, Oncology and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy. Electronic address:

Background: Drug-induced interstitial lung disease (DIILD) is a form of interstitial lung disease resulting from exposure to drugs causing inflammation and possibly interstitial fibrosis. Antineoplastic drugs are the primary cause of DIILD, accounting for 23%-51% of cases, with bleomycin, everolimus, erlotinib, trastuzumab-deruxtecan and immune checkpoint inhibitors being the most common causative agents. DIILD can be difficult to identify and manage, and there are currently no specific guidelines on the diagnosis and treatment of DIILD caused by anticancer drugs. Read More

View Article and Full-Text PDF

Nintedanib-A case of treating concurrent idiopathic pulmonary fibrosis and non-small cell lung cancer.

Respirol Case Rep 2022 Feb 12;10(2):e0902. Epub 2022 Jan 12.

Respiratory Department Blacktown Hospital Sydney New South Wales Australia.

Treating advanced lung cancer in patients with pulmonary fibrosis can be challenging due to increased risks of drug-induced and radiation-induced pneumonitis. We present the case of a 78-year-old female with stage IIIB lung adenocarcinoma and idiopathic pulmonary fibrosis (IPF). Following partial response to platinum-based chemotherapy, she was started on maintenance pemetrexed, but this was stopped due to bone marrow suppression and kidney injury. Read More

View Article and Full-Text PDF
February 2022

Unilateral methotrexate-induced lung injury with foreign bodies in the airway: A case report.

Respir Med Case Rep 2022 1;36:101573. Epub 2022 Jan 1.

Department of Respiratory Medicine, Toshima Hospital, Tokyo Metropolitan Health and Hospitals Corporation, 33-1, Sakaecho, Itabashi-Ku, Tokyo, 173-0015, Japan.

A 75-year-old woman who had been taking methotrexate presented to our hospital for fever and dry cough. Chest computed tomography showed ground-glass opacity in the upper lobe of the right lung and foreign bodies in the lower lobe of the right bronchus. During bronchoscopy, foreign bodies were removed from the airway. Read More

View Article and Full-Text PDF
January 2022

Optic neuropathy secondary to granulomatosis with polyangiitis in a patient with Graves' disease: a case report.

J Med Case Rep 2021 Dec 29;15(1):618. Epub 2021 Dec 29.

Department of Otolaryngology Head and Neck Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.

Background: Dysthyroid optic neuropathy is the most commonly suspected diagnosis of optic neuropathy in Graves' patients; however, other causes need to be ruled out. We present a unique case of optic neuropathy secondary to hypertrophic pachymeningitis with antineutrophil cytoplasmic antibody-associated vasculitis, which was suspected to be antithyroid drug related.

Case Presentation: A 79-year-old Japanese male presented with acute visual loss in the left eye. Read More

View Article and Full-Text PDF
December 2021

Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer.

J Oncol Pharm Pract 2022 Apr 22;28(3):740-745. Epub 2021 Dec 22.

Department of Medical Oncology, 64222Necmettin Erbakan University School of Medicine, Konya, Turkey.

Introduction: Trastuzumab emtansine (TDM-1) is an antibody-drug conjugate effective in human epidermal growth factor receptor-2 - expressing advanced breast cancer. Pulmonary complications of TDM-1 are rarely reported. TDM-1-associated interstitial lung disease is referred to as pneumonitis. Read More

View Article and Full-Text PDF

Energy-sparing by 2-methyl-2-thiazoline protects heart from ischaemia/reperfusion injury.

ESC Heart Fail 2022 02 2;9(1):428-441. Epub 2021 Dec 2.

Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Aims: Cardiac ischaemia/reperfusion (I/R) injury remains a critical issue in the therapeutic management of ischaemic heart failure. Although mild hypothermia has a protective effect on cardiac I/R injury, more rapid and safe methods that can obtain similar results to hypothermia therapy are required. 2-Methyl-2-thiazoline (2MT), an innate fear inducer, causes mild hypothermia resulting in resistance to critical hypoxia in cutaneous or cerebral I/R injury. Read More

View Article and Full-Text PDF
February 2022

Interstitial lung disease in a woman with rheumatoid arthritis treated with denosumab: A case report.

Mod Rheumatol Case Rep 2022 Jun;6(2):155-159

Department of Orthopedic Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

The present report describes the case of an 84 year old female Japanese patient with rheumatoid arthritis (RA) who experienced exacerbation of interstitial lung disease (ILD) after denosumab (Dmab) treatment. The onset of RA occurred in 2008, and the patient had been treated with intravenous or subcutaneous injection of tocilizumab since 2009. In July 2013, she experienced a lumbar vertebral fracture and began treatment with 60 mg Dmab injection every 6 months in January 2014. Read More

View Article and Full-Text PDF

Sertraline-Associated Interstitial Lung Disease: A case series and Literature Review.

Sarcoidosis Vasc Diffuse Lung Dis 2021 30;38(3):e2021027. Epub 2021 Sep 30.

Pulmonary Institute, Rabin Medical Center, Petah Tikva, Israel.

Sertraline-associated interstitial lung disease (ILD) is a rare entity. A search of the English medical literature retrieved only 9 such cases. We report herein on an additional 12 patients who developed ILD during treatment with sertraline. Read More

View Article and Full-Text PDF
September 2021

Drug-induced hypersensitivity syndrome caused by minodronic acid hydrate.

BMC Pulm Med 2021 Nov 7;21(1):350. Epub 2021 Nov 7.

Department of Respiratory Medicine, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8953, Japan.

Background: Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is an important adverse reaction caused by a few drugs. Reactivation of human herpesvirus 6 (HHV-6) is known to be associated with its pathogenesis. DIHS occasionally manifests as pulmonary lesions with a variety of imaging findings. Read More

View Article and Full-Text PDF
November 2021

Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury.

J Hepatol 2022 03 1;76(3):558-567. Epub 2021 Nov 1.

Department of Cardiology, Daping Hospital, Third Military Medical University, Chongqing, China; Chongqing Key Laboratory for Hypertension Research, Chongqing Cardiovascular Clinical Research Center, Chongqing Institute of Cardiology, Chongqing, PR China; State Key Laboratory of Trauma, Burns and Combined Injury, Daping Hospital, The Third Military Medical University, Chongqing, PR China; Cardiovascular Research Center of Chongqing College, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Chongqing, PR China. Electronic address:

Background & Aims: Drug-induced liver injury (DILI) remains challenging to treat and is still a leading cause of acute liver failure. MG53 is a muscle-derived tissue-repair protein that circulates in the bloodstream and whose physiological role in protection against DILI has not been examined.

Methods: Recombinant MG53 protein (rhMG53) was administered exogenously, using mice with deletion of Mg53 or Ripk3. Read More

View Article and Full-Text PDF

Delayed onset of fat embolus in the cerebral venous system after breast and hip augmentation: a case report.

BMC Neurol 2021 Oct 26;21(1):411. Epub 2021 Oct 26.

Department of Neuro-intensive Care Unit, West China Hospital, Sichuan University, Chengdu, 610041, China.

Background: Cerebral fat embolism (CFE) is a subtype of fat embolism syndrome which tends to cause ischemic cerebral infarction. Fat embolism in the cerebral venous system have not been reported. We hereby present a rare case of fat embolus formed in the cerebral venous system 10 days after cosmetic surgery, and describe our management of this patient. Read More

View Article and Full-Text PDF
October 2021

18F-FDG PET/CT imaging in the diagnosis of drug-induced lung disease and pulmonary infection in lymphoma.

Medicine (Baltimore) 2021 Sep;100(37):e27107

Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

Objective: Lymphoma is a hematological disease with high prevalence. Multi-cycle chemotherapy (CHT) or local radiotherapy is applied usually; however, adverse events have been reported, such as drug-induced lung disease (DILD). Positron emission tomography/computed tomography (PET/CT) is often used to evaluate the lesion, treatment effect, and prognosis of lymphoma. Read More

View Article and Full-Text PDF
September 2021

Infliximab-induced interstitial lung disease.

BMJ Case Rep 2021 Oct 13;14(10). Epub 2021 Oct 13.

Department of Respiratory Medicine, University Hospital of Patras, Patras, Greece.

A 70-year-old man was referred to our respiratory department with non-productive cough over the past 6 months. High-resolution CT revealed reticular pattern with basal and peripheral predominance, centrilobular nodules and mild ground glass opacities. Serology tests were normal and bronchoalveolar lavage revealed lymphocytosis. Read More

View Article and Full-Text PDF
October 2021

Gemcitabine and nab-paclitaxel induced interstitial pneumonia.

Diagn Interv Imaging 2021 Dec 7;102(12):763-764. Epub 2021 Oct 7.

Université de Paris, Faculté de Médecine, Paris 75006, France; Department of Radiology, Hôpital Cochin, GH APHP.Centre, Paris 75014, France.

View Article and Full-Text PDF
December 2021

COVID-19 vaccine induced interstitial lung disease.

J Infect Chemother 2022 Jan 20;28(1):95-98. Epub 2021 Sep 20.

Department of Emergency and Critical Care Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan.

A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Read More

View Article and Full-Text PDF
January 2022

Chest high-resolution computed tomography in patients with connective tissue disease: pulmonary conditions beyond "the usual suspects".

Curr Probl Diagn Radiol 2021 Aug 29. Epub 2021 Aug 29.

Institute of Radiology, Department of Medicine, University of Udine, "S. Maria della Misericordia" University Hospital, p.le S. Maria della Misericordia, 15 - 33100 Udine, Italy.

The term "connective tissue diseases" (CTDs) refers to a heterogeneous group of autoimmune disorders, including systemic sclerosis, rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus, polymyositis, dermatomyositis, antisynthetase syndrome, and mixed connective tissue disease. Chest high-resolution computed tomography (HRCT) is the imaging method of choice for evaluating patients with known or suspected CTD-related interstitial lung disease (CTD-ILD), a complication accounting for substantial morbidity and mortality. While specific HRCT patterns and signs of CTD-ILD have been extensively described (hence the designation "the usual suspects"), the knowledge of various, less frequent conditions involving the lungs in patients with CTD would help the radiologist produce a clinically valuable report, thus potentially influencing patient management. Read More

View Article and Full-Text PDF

First report of COVID-19-associated rhino-orbito-cerebral mucormycosis in pediatric patients with type 1 diabetes mellitus.

J Mycol Med 2021 Dec 4;31(4):101203. Epub 2021 Sep 4.

Department of Neuromicrobiology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India. Electronic address:

Coronavirus disease 2019 (COVID-19) is a major public health problem worldwide. These patients are at increased risk of developing secondary infections due to a combination of virus- and drug-induced immunosuppression. Recently, several countries have reported an emergence of COVID-19 associated mucormycosis (CAM), particularly among patients with uncontrolled diabetes, with India reporting an alarming increase in rhino-orbito-cerebral mucormycosis (ROCM) in post-COVID cases. Read More

View Article and Full-Text PDF
December 2021

Commentary: Imaging Biomarkers and Pathobiological Profiling in a Rat Model of Drug-Induced Interstitial Lung Disease (DIILD) Induced by Bleomycin.

Front Physiol 2021 28;12:691650. Epub 2021 Jul 28.

Department of Physiology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.

View Article and Full-Text PDF

An update on interstitial lung disease.

Br J Hosp Med (Lond) 2021 Jul 20;82(7):1-14. Epub 2021 Jul 20.

Interstitial Lung Disease Unit, Respiratory Medicine Department, Wythenshawe Hospital, Manchester, UK.

Interstitial lung diseases are a complex group of conditions that cause inflammation and scarring of the lung interstitium. This article discusses the diagnosis and management of common interstitial lung diseases including idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, connective tissue disease associated-interstitial lung disease, sarcoidosis and drug-induced interstitial lung disease. A multidisciplinary approach to diagnosis of interstitial lung disease is the gold standard; key history and examination features, blood panel, pulmonary function tests, high resolution computed tomography imaging, and when required bronchoalveolar lavage and lung biopsy results are discussed to reach a multidisciplinary consensus diagnosis. Read More

View Article and Full-Text PDF

Radiation-Induced Lung Injury-Current Perspectives and Management.

Clin Pract 2021 Jul 1;11(3):410-429. Epub 2021 Jul 1.

Division of Pulmonary Diseases and Critical Care, Yale-New Haven Health Bridgeport Hospital, 267 Grant Street, Bridgeport, CT 06610, USA.

Radiotherapy plays an important role in the treatment of localized primary malignancies involving the chest wall or intrathoracic malignancies. Secondary effects of radiotherapy on the lung result in radiation-induced lung disease. The phases of lung injury from radiation range from acute pneumonitis to chronic pulmonary fibrosis. Read More

View Article and Full-Text PDF

Drug-induced QTc interval prolongation in PCR-positive non-ICU COVID-19 patients with diverse findings on chest computed tomography.

Int J Clin Pract 2021 Oct 12;75(10):e14583. Epub 2021 Jul 12.

Department of Cardiology, Akhisar Mustafa Kirazoglu State Hospital, Manisa, Turkey.

Background: Some of the drugs used for the treatment of coronavirus disease (COVID-19) can increase the risk of corrected QT (QTc) interval prolongation, which may trigger arrhythmia or even death. Due to the low sensitivity of the reverse transcriptase-polymerase chain reaction (RT-PCR) test, chest computed tomography (CT) imaging is being used for COVID-19 diagnostic correlation and to evaluate whether there is pneumonic involvement in the lung.

Objective: In this study, we aimed to investigate the correlation between lung changes on CT and QTc interval changes on ECG in non-ICU patients with COVID-19 who have a positive PCR test when using drugs that can prolong the QTc interval. Read More

View Article and Full-Text PDF
October 2021

Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID-19 patients.

Allergy 2022 02 19;77(2):595-608. Epub 2021 Jul 19.

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

Background: Coronavirus disease-2019 (COVID-19) has been associated with cutaneous findings, some being the result of drug hypersensitivity reactions such as maculopapular drug rashes (MDR). The aim of this study was to investigate whether COVID-19 may impact the development of the MDR.

Methods: Blood and skin samples from COVID-19 patients (based on a positive nasopharyngeal PCR) suffering from MDR (COVID-MDR), healthy controls, non-COVID-19-related patients with drug rash with eosinophilia and systemic symptoms (DRESS), and MDR were analyzed. Read More

View Article and Full-Text PDF
February 2022

Imaging Features of Pulmonary Immune-related Adverse Events.

J Thorac Oncol 2021 09 1;16(9):1449-1460. Epub 2021 Jun 1.

Department of Radiodiagnostic and Interventional Radiology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

Pulmonary immune-related adverse events represent rare but potentially severe side effects of immunotherapies. Diagnosis is often challenging, as symptoms and imaging features are not specific and may mimic other lung diseases, thus potentially delaying appropriate patient management. In this setting, an accurate imaging evaluation is essential for a prompt detection and correct management of these drug-induced lung diseases. Read More

View Article and Full-Text PDF
September 2021

Wavelength-Tunable, Long Lifetime, and Biocompatible Luminescent Nanoparticles Based on a Vitamin E-Derived Material for Inflammation and Tumor Imaging.

Small 2021 06 24;17(25):e2100045. Epub 2021 May 24.

Department of Pharmaceutics, College of Pharmacy, Third Military Medical University (Army Medical University), Chongqing, 400038, China.

Luminescence imaging is one of the most effective noninvasive strategies for detection and stratification of inflammation and oxidative stress that are closely related to the pathogenesis of numerous acute and chronic diseases. Herein biocompatible nanoparticles based on a peroxalate ester derived from vitamin E (defined as OVE) are developed. In combination with different fluorophores, OVE can generate luminescence systems with emission wavelengths varying from blue to the near-infrared light in its native and nanoparticle forms, in the presence of hydrogen peroxide (H O ). Read More

View Article and Full-Text PDF

Drug-induced organ injury in coronavirus disease 2019 pharmacotherapy: Mechanisms and challenges in differential diagnosis and potential protective strategies.

J Biochem Mol Toxicol 2021 Jul 11;35(7):e22795. Epub 2021 May 11.

Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

The world is currently facing an unprecedented pandemic caused by a newly recognized and highly pathogenic coronavirus disease 2019 (COVID-19; induced by SARS-CoV-2 virus), which is a severe and ongoing threat to global public health. Since COVID-19 was officially declared a pandemic by the World Health Organization in March 2020, several drug regimens have rapidly undergone clinical trials for the management of COVID-19. However, one of the major issues is drug-induced organ injury, which is a prominent clinical challenge. Read More

View Article and Full-Text PDF

Differentiation of pulmonary complications with extensive ground-glass attenuation on high-resolution CT in immunocompromised patients.

Jpn J Radiol 2021 Sep 4;39(9):868-876. Epub 2021 May 4.

Department of Radiology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan.

Purpose: The purpose of this study was to compare the high-resolution CT (HRCT) findings of pulmonary infectious and noninfectious complications with extensive ground-glass attenuation (GGA) in immunocompromised patients.

Materials And Methods: One hundred fifty-two immunocompromised patients with pulmonary complications that showed extensive GGA (> 50% of the whole lung on HRCT) were included in this study. The diagnoses of the 152 patients were as follows: pneumocystis pneumonia (PCP), n = 82; drug-induced pneumonia, n = 38; bacterial pneumonia, n = 9; cytomegalovirus pneumonia, n = 6; idiopathic pneumonia syndrome, n = 6; diffuse alveolar hemorrhage (DAH), n = 4; fungal infection, n = 3; tuberculosis, n = 2 and pulmonary edema, n = 2. Read More

View Article and Full-Text PDF
September 2021

Late-onset programmed cell death protein-1 inhibitor-induced pneumonitis after cessation of nivolumab or pembrolizumab in patients with advanced non-small cell lung cancer: a case series.

Transl Lung Cancer Res 2021 Mar;10(3):1576-1581

Respiratory Medicine, Kanazawa University Hospital, Ishikawa, Japan.

Awareness of the immune-related adverse event of programmed cell death protein-1 (PD-1) inhibitor-induced pneumonitis is important. Herein, we report the clinical course of 3 patients suspected to have PD-1 inhibitor-induced pneumonitis after cessation of PD-1 inhibitor treatment. In case 1, a 62-year-old man was diagnosed with stage IVA adenocarcinoma. Read More

View Article and Full-Text PDF